RXPenisEnlarger
Clinical Trials
Before & After
Testimonials
Informational Video
Frequently Asked Questions
Certifications
Order Now!
Home
|
Penile enlargement without surgery with the RXPenisEnlarger
Scientific Research presented in the 1st
Virtual Sexology and Hispanoamerican Sexual Education Congress
(February -2001).
1. Introduction:
When the human tissues are submitted to a
force of traction, they react by increasing in size.
Based on this
principle of external traction the
RXPenisEnlarger® was designed. It is
able to exert a gradual traction force of 600 to 1500
grams.
The device consists of a plastic ring, where
the penis is introduced and from where 2 dynamic metallic rods
that originate the traction. In the superior part there is a
plastic support where a silicone band holds the glands in place.
Based on our clinical experience the
traction device yields the following resutls:
- An increase in the length of the penis
in erection and flaccidity.
- An increase in the perimeter of the
penis in erection and flaccidity.
- This results will be analyzed
statistically to be verified and quantified
2. Materials and Methods
Number of patients: 37
patients, ages between 22 and 60 years of age. These men
proceed from different cities in Spain.
Selection of patients:
patients included were healthy men with normal erection
capabilities and without penile surgeries. Patients with penile or
other diseases where excluded from the studies.
Traction device: The
RXPenisEnlarger®, German penile traction device.
Traction Force: 600 grams during
1st month, 900 grams during 2nd month, 1100 grams during 3th and 4th
month, and 1200 grams during 5th and 6th month.
Usage period: 10 hours a day,
during every day of the month for a period of 3-6 months.
3. Results - 3cm = 1 inch
3.1.- INCREASE IN LENGTH IN ERECTION:
The average increase in the length of the
penis in erection by month is of 0.4726 cm. The standard
deviation is of 0.1329 cm. The confidential interval of 95% is of
[0.4283 ; 0.5169] which indicates a minimal gain in the
population of 0.4283 cm/month.
3.2.- INCREMENT IN LENGTH IN
THE FLACCID STATE
The average monthly increment in
longitude of the penis in the flaccid state is 0.4834 cm and
the typical deviation is 0.1983 cm. The confidence interval of 95%
is of [0.4173 ; 0.5495] and indicates a minimum increase in the
population of 0.4173 cm/month.
3.3.- VARIABILITY:
The variability in the increment in
longitude in erection is different from that of flaccidity,
being the difference in variance significant ( p= 0.003 ) which
indicates a greater dispersion of the increases in length
during flaccidity than in erection.
3.4.- THE INCREMENT IN
LONGITUDE DOES NOT DEPEND ON THE AGE:
A very interesting result was that the
increment in longitude does not depend on the age of the
patient, since the coefficient of the linear correlation is not
significant ( r=0.008, p=0.961). In other words, the age of the
patient does not effect the increment in longitude.
3.5 - LONGITUDE INCREASE IN
ERECTION STATE DEPENDING ON USE:
Dividing the population studied in four sub
groups depending on the usage time of the RXPenisEnlarger®.
we obtain the following results.
Three months usage:
The median longitude increment in erection state was 1.4118,
obtaining a median growth of 10.5580% over the initial
longitude.The confidence interval of 95% of the studied population
was ( 1.1522; 1.6713) which shows a median minimal growth of
1.1522 cm in three months.
Four months usage:
The median longitude increment in erection state was 1.8462,
obtaining a median growth of 14.1113% over the initial
longitude. The confidence interval of 95% of the studied
population was(1.5809; 2.1114) which shows a median minimal
growth of 1.5809 cm in four months.
* Meses = Months
Five months usage:
The median longitude increment in erection state was 2.2750,
obtaining a median growth of 16.6303% over the initial
longitude. The confidence interval of 95% of the population
studied was (1.7656; 2.7844) which shows a median minimal
growth of 1.7656 cm in four months.
Six months usage:
The median longitude increment in erection state was 3.3333,
obtaining a median growth of 27.5% over the initial longitude.
The confidential interval of 95% of the population studied was
(2.8162; 3.8504) which shows a median minimal growth of 2.8162
cm in six months.
The samples corresponding to five and
six months are very small which makes small intervals and less reliable.
* Meses = Months
3.6 - DISTRIBUTION:
Although the variables considered in the
population are not normal, the median samples, have normal
distribution since the amount of the sample is greater than 20.
3.7 - ABBREVIATIONS:
| Inc-Long-Erec |
Longitude increment in erection state |
| DL erec |
Change in Longitude increment in erection state |
| I.L.ERT |
Longitude increment in erection as a function of the
time variable |
| I.L.FLAC |
Longitude increment in flaccid state |
| DL flac |
Change in Longitude increment in flaccid state |
| I.L.FLT |
Longitude increment in flaccid state in function of time |
| Inc-Long-Erec |
Longitude increment in erection state |
| % I Long-Erec |
Longitude increment percentage in erection state. |
4. Conclusions
The use of the German traction device (
RXPenisEnlarger� ) will increase the length of the penis, both in the
erectile and flaccid state.
The increase in length, both in and
flaccidity, is directly proportional to the time of use.
The increase in length both in erection and
flaccidity, does not depend on the natural size of the patient.
The average growth in length of the penis in
cm/month in 95% of the patients was between 0.4283 and 0.5163 in
erection, and between 0.4173 and 0.5495 in flaccidity.
The increments of change in length of the
penis in erection are more uniform than those in flaccidity which
tend to be more disparate .
The increment of change in the length of the
penis in erection is not relative to the age of the patient.
The use of the penile traction device will
increase the perimeter of the penis, both in erection and flaccidity.
The average growth in perimeter in cm/month
in 95% of the patients was between 0.6111 and 1.0200 in erection,
and between 0.6386 and 1.0425 in flaccidity. Treatment was 3-6
months duration.
5. Anex
PATIENT RESULTS (Using the RXPenisEnlarger®):
Name
|
Age
|
Date
|
L-Er1
|
L-Fl1
|
P-Er1
|
P-Fl1
|
Mo
|
L-Er2
|
L-Fl2
|
P-Er2
|
P-Fl2
|
| LAA
|
60
|
15.1.98
|
12.0
|
8.0
|
12.0
|
10.0
|
3.0
|
13.5
|
9.0
|
13.5
|
10.5
|
| EAG
|
37
|
30.1.98
|
14.5
|
8.0
|
12.0
|
8.5
|
4.0
|
16.5
|
9.5
|
13.0
|
10.5
|
| VA
|
27
|
26.11.97
|
16.3
|
10.4
|
13.9
|
10.1
|
3.0
|
17.8
|
12.5
|
14.5
|
11.5
|
| EAA
|
46
|
15.3.98
|
14.5
|
10.5
|
12.0
|
10.0
|
6.0
|
17.6
|
15.7
|
13.2
|
11.2
|
| JBV
|
25
|
27.3.98
|
15.0
|
8.0
|
13.0
|
9.0
|
3.0
|
16.6
|
9.5
|
13.3
|
10.5
|
| ABB
|
39
|
29.6.98
|
14.0
|
11.0
|
13.0
|
11.0
|
3.0
|
15.5
|
12.5
|
14.0
|
12.0
|
|
CBG
|
37
|
19.1.98
|
12.5
|
6.0
|
12.0
|
9.0
|
4.0
|
14.0
|
8.8
|
12.5
|
9.4
|
|
JBL
|
25
|
7.5.98
|
13.7
|
9.0
|
11.5
|
10.0
|
4.0
|
16.3
|
11.5
|
13.5
|
12.0
|
| JCB
|
27
|
19.11.97
|
13.0
|
8.0
|
14.5
|
12.0
|
6.0
|
16.4
|
11.1
|
14.2
|
12.2
|
| JJCA
|
33
|
1.6.98
|
10.5
|
4.9
|
11.0
|
9.5
|
3.0
|
12.0
|
5.5
|
11.5
|
9.5
|
| JCA
|
32
|
4.2.98
|
14.0
|
10.0
|
10.0
|
9.0
|
4.0
|
15.9
|
12.0
|
12.2
|
10.5
|
| ODV
|
25
|
4.3.98
|
16.5
|
9.5
|
13.0
|
9.7
|
3.0
|
18.0
|
11.0
|
13.3
|
10.0
|
| PDS
|
22
|
10.6.98
|
14.4
|
8.3
|
11.0
|
7.8
|
3.0
|
15.8
|
9.0
|
11.6
|
8.3
|
| AGM
|
41
|
26.11.98
|
13.0
|
9.0
|
11.0
|
10.0
|
4.0
|
15.0
|
9.5
|
11.0
|
10.0
|
| MGF
|
32
|
29.9.97
|
12.5
|
5.5
|
12.5
|
10.0
|
4.0
|
14.5
|
8.0
|
13.0
|
10.0
|
| AHM
|
44
|
5.3.98
|
11.5
|
8.0
|
13.0
|
12.0
|
3.0
|
13.0
|
9.5
|
14.0
|
12.0
|
| AAMP
|
37
|
12.3.98
|
12.7
|
7.0
|
10.5
|
7.5
|
3.0
|
14.0
|
9.0
|
11.0
|
9.0
|
| JLMO
|
34
|
30.1.98
|
14.8
|
11.0
|
11.0
|
9.3
|
4.0
|
15.8
|
11.0
|
12.7
|
9.3
|
| JAMV
|
41
|
28.7.97
|
17.0
|
10.0
|
14.0
|
12.5
|
5.0
|
19.6
|
12.3
|
15.0
|
13.5
|
| FOR
|
8%
|
9.11.97
|
12.5
|
7.0
|
10.0
|
9.0
|
5.0
|
14.5
|
11.0
|
11.0
|
10.5
|
| ROM
|
28
|
12.11.97
|
16.0
|
8.5
|
13.0
|
9.0
|
5.0
|
18.0
|
12.5
|
13.5
|
10.5
|
| JPC
|
33
|
16.1.98
|
13.7
|
7.2
|
12.3
|
10.1
|
3.0
|
16.7
|
8.7
|
13.1
|
10.9
|
| JAPG
|
29
|
4.11.97
|
10.0
|
8.0
|
12.0
|
10.0
|
6.0
|
13.5
|
11.5
|
13.0
|
11.0
|
| FPR
|
8%
|
20.3.98
|
10.5
|
7.0
|
12.0
|
10.0
|
3.0
|
11.3
|
7.3
|
12.7
|
10.0
|
| JPF
|
42
|
23.3.98
|
13.0
|
7.0
|
13.0
|
10.0
|
3.0
|
14.5
|
8.5
|
13.0
|
10.5
|
| AJRF
|
26
|
28.11.97
|
14.0
|
9.0
|
13.0
|
9.0
|
4.0
|
16.0
|
10.7
|
13.0
|
10.0
|
| ARR
|
58
|
7.10.97
|
11.0
|
7.0
|
11.0
|
9.0
|
3.0
|
12.0
|
8.0
|
12.0
|
10.0
|
| RRG
|
25
|
25.11.97
|
14.5
|
11.0
|
11.0
|
10.0
|
3.0
|
15.0
|
12.4
|
11.7
|
10.8
|
| CSM
|
35
|
24.2.98
|
15.0
|
9.0
|
11.0
|
9.0
|
3.0
|
16.5
|
11.0
|
12.0
|
10.0
|
| ASE
|
35
|
20.3.98
|
12.5
|
7.5
|
11.5
|
9.0
|
4.0
|
14.5
|
9.5
|
12.5
|
10.5
|
| ASPA
|
42
|
7.11.97
|
14.0
|
7.5
|
12.0
|
9.0
|
4.0
|
16.0
|
9.5
|
13.0
|
10.5
|
| SSF
|
27
|
15.8.97
|
14.5
|
7.0
|
14.5
|
8.0
|
3.0
|
15.9
|
8.0
|
15.0
|
8.7
|
| ISB
|
22
|
23.9.97
|
11.5
|
7.5
|
11.0
|
9.5
|
4.0
|
13.5
|
10.2
|
11.3
|
10.3
|
| FT
|
53
|
19.11.97
|
14.5
|
10.0
|
13.0
|
10.0
|
3.0
|
16.0
|
11.5
|
13.5
|
10.5
|
| EVC
|
24
|
29.12.97
|
11.0
|
7.0
|
11.5
|
9.0
|
5.0
|
13.5
|
9.0
|
12.5
|
10.5
|
| PV
|
33
|
8.10.97
|
12.0
|
8.5
|
15.5
|
13.0
|
4.0
|
13.0
|
9.5
|
16.0
|
13.0
|
| JSVS
|
32
|
24.1.98
|
12.0
|
6.0
|
10.5
|
9.0
|
4.0
|
14.0
|
8.5
|
12.5
|
9.5
|
Mo = Month
L-Erec1 = Length in Erection initial
L-Flac1 = Length in Flaccidity inicial
P-Erec1 = Perimeter in Erection initial
P-Flac1 = Perimeter in Flaccidity inicial
L-Erec2 = Length in Erection final
L-Flac2 = Length in Flaccidity final
P-Erec2 = Perimeter in Erection final
P-Flac2 = Perimeter in Flaccidity final
Learn More | Order Now
|
|
|
|
If you have or suspect an illness or have a health concern, always consult with your physician or health care provider. We have used our best judgment in compiling this information, however, the information presented may not have been evaluated by the Food and Drug Administration. Any reference to a specific product is for your information only and is not intended to diagnose, treat, cure, or prevent any disease.
Feel21 Inc. - 1071 NW 54 Street,
Ft. Lauderdale, FL 33309 (954)-776-4499 Fax: (954)-776-5098
All trademarks and
registered trademarks are of their respective companies. © Copyright
2004 RxPenisEnlarge.com, all rights reserved. Terms of Service, Legal Disclaimer and Full Trademark Information
|
|
